This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US FTC to scrutinize drug patents listed in FDA Orange Book; improper listings may be litigated, official warns

By Khushita Vasant ( November 29, 2023, 01:22 GMT | Insight) -- Pharmaceutical companies were put on notice today by a senior Federal Trade Commission enforcer over improperly listed patents that the agency says could chill generic drug competition in the US, with a warning that the FTC may potentially litigate against such anticompetitive conduct.Pharmaceutical companies were put on notice today by a senior Federal Trade Commission enforcer over improperly listed patents that could chill generic drug competition in the US, with a warning that the agency may potentially litigate against such anticompetitive conduct....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections